Skip to Content

Lixisenatide use while Breastfeeding

Drugs containing Lixisenatide: Soliqua, Adlyxin

Medically reviewed by Drugs.com. Last updated on Nov 14, 2020.

Lixisenatide Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of lixisenatide during breastfeeding. Because lixisenatide is a large peptide molecule with a molecular weight of 4858 daltons, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, lixisenatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

Substance Identification

Substance Name

Lixisenatide

CAS Registry Number

320367-13-3

Drug Class

  • Breast Feeding
  • Lactation
  • Hypoglycemic Agents
  • Incretins
  • Glucagon-Like Peptide-1 Agonists
  • GLP-1 Agonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.